文献速递前列腺癌

原发前列腺癌中呈现转移生物学特征的分子亚群

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
PubMed 文献 · Eur Urol · 2017-04-10

研究通过无监督层次聚类分析70例原发切除、31例转移淋巴结和25例正常前列腺样本的基因表达数据,识别出与转移性疾病生物学相似的原发前列腺癌分子亚群,并开发出70转录本特征(转移检测)。在322例根治性前列腺切除样本中验证,转移检测阳性患者生化复发风险(多变量HR 1.62)和转移复发风险(多变量HR 3.20)升高。与CAPRA-S联合模型可更好识别高复发风险患者。

要点

  • 原发前列腺癌中存在与转移性疾病生物学相似的分子亚群。
  • 转移检测阳性与生化复发风险升高相关(多变量HR 1.62)。
  • 转移检测阳性与转移复发风险升高相关(多变量HR 3.20)。

核心结论

  • 转移检测可能识别具有转移潜能的原发前列腺癌分子亚群。

研究设计与样本

  • 无监督层次聚类分析70例原发切除、31例转移淋巴结和25例正常前列腺样本的基因表达数据。
  • 使用来自四个中心的322例根治性前列腺切除样本进行独立验证,平均随访50.3个月。

临床怎么用

  • 转移检测可能提高识别根治性前列腺切除术后转移复发风险患者的能力。
  • 作者认为应在该较高风险人群中评估辅助治疗的影响。

局限性

  • 研究为回顾性性质,原文将其列为潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 4-25% of patients with early prostate cancer develop disease recurrence following radical prostatectomy. OBJECTIVE: To identify a molecular subgroup of prostate cancers with metastatic potential at presentation resulting in a high risk of recurrence following radical prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: Unsupervised hierarchical clustering was performed using gene expression data from 70 primary resections, 31 metastatic lymph nodes, and 25 normal prostate samples. Independent assay validation was performed using 322 radical prostatectomy samples from four sites with a mean follow-up of 50.3 months. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Molecular subgroups were identified using unsupervised hierarchical clustering. A partial least squares approach was used to generate a gene expression assay. Relationships with outcome (time to biochemical and metastatic recurrence) were analysed using multivariable Cox regression and log-rank analysis. RESULTS AND LIMITATIONS: A molecular subgroup of primary prostate cancer with biology similar to metastatic disease was identified. A 70-transcript signature (metastatic assay) was developed and independently validated in the radical prostatectomy samples. Metastatic assay positive patients had increased risk of biochemical recurrence (multivariable hazard ratio [HR] 1.62 [1.13-2.33]; p=0.0092) and metastatic recurrence (multivariable HR=3.20 [1.76-5.80]; p=0.0001). A combined model with Cancer of the Prostate Risk Assessment post surgical (CAPRA-S) identified patients at an increased risk of biochemical and metastatic recurrence superior to either model alone (HR=2.67 [1.90-3.75]; p<0.0001 and HR=7.53 [4.13-13.73]; p<0.0001, respectively). The retrospective nature of the study is acknowledged as a potential limitation. CONCLUSIONS: The metastatic assay may identify a molecular subgroup of primary prostate cancers with metastatic potential. PATIENT SUMMARY: The metastatic assay may improve the ability to detect patients at risk of metastatic recurrence following radical prostatectomy. The impact of adjuvant therapies should be assessed in this higher-risk population.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Walker SM, Knight LA, McCavigan AM, et al. Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. Eur Urol. 2017. PMID: 28408174. doi:10.1016/j.eururo.2017.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。